Genetic risk scores may compound rather than solve the issue of prostate cancer overdiagnosis

Br J Cancer. 2023 Jan;128(1):1-2. doi: 10.1038/s41416-022-02080-2. Epub 2022 Nov 28.

Rachel H Horton^{1

2

3

4}, Malcolm G Dunlop⁵, Richard S Houlston⁶, Anneke Lucassen^{1

3

4}, Margaret McCartney⁷, Alan McNeill^{8

9}, Amit Sud^{10

11}

¹ Clinical Ethics and Law, Faculty of Medicine, University of Southampton, Southampton, UK.
² Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK.
³ Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
⁴ Centre for Personalised Medicine, University of Oxford, Oxford, UK.
⁵ Colon Cancer Genetics Group, Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
⁶ Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
⁷ Population and Behavioural Science Division, School of Medicine, University of St Andrews, St Andrews, UK.
⁸ Edinburgh Urological Cancer Group, University of Edinburgh, Western General Hospital, Edinburgh, UK.
⁹ School of Engineering and Physical Sciences, Heriot Watt University, Edinburgh, UK.
¹⁰ Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK. amit.sud@icr.ac.uk.
¹¹ Haemato-oncology Unit, The Royal Marsden Hospital NHS Foundation Trust, Sutton, UK. amit.sud@icr.ac.uk.

No abstract available

Publication types